anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
At the Baseline Visit, following satisfaction of entry criteria and screening procedures, all subjects will be applying two products on their faces, each on half face. The side of face receiving each product is randomly assigned. One group will use tretinoin facial gel on the left side and adapalene facial gel on the right side of the face daily for two consecutive weeks after washing with study-supplied facial wash. The other group will use the same products, but on opposite sides of the face for two consecutive weeks after washing with the same study-supplied facial wash.

Subjects will return to the study center every weekday morning for evaluation and for the morning application of both study products. Study personnel will monitor application on the weekdays. There will be a daily clinical evaluation of skin irritation by a blinded dermatologist and by subjects. At baseline and at the end of each week subjects will be photographed and have chromometer readings.
An occupational therapy support device according to the present disclosure includes an input data reception unit, an estimation unit, and an estimated data output unit. The input data reception unit receives the input of input data including sleep data of the subject of occupational therapy evaluation and the basic data of the subject. The estimation unit inputs the received input data to a trained artificial intelligence to cause the artificial intelligence to estimate the activity of daily living data of the subject and the physical function data of the subject. The estimated data output unit outputs the data estimated by the artificial intelligence. The sleep data includes the number of turns, the number of body movements, the number of times of going to the bathroom, and the time in the bathroom. The basic data includes the age, height, weight, and medical history. The activity of daily living data includes eating, going to the bathroom, defecation, transfer to the bathroom, locomotion/walk, comprehension, problem solving, and memory. The physical function data includes the grip strength. This configuration enables a user to obtain objective data that does not depend on the evaluator and is useful for performing occupational therapy.
Background: Despite increasing sub-specialization, general surgeons continue to perform oncologic thoracic surgeries. Our objective was to determine whether general surgery resident participation in thoracic surgery affects surgical quality or oncologic outcomes. We hypothesized that patient outcomes with and without resident participation would be similar. Methods: We retrospectively reviewed the electronic health records of patients with stage 0-IV lung cancer undergoing oncologic pulmonary resection at BLINDED FOR REVIEW during an 11-year period (2012-2022). Patients younger than 18 years or older than 85 years were excluded, as were those who had incomplete follow-up data or were unregistered in our institutional cancer registry. Patients were divided into groups based on whether residents or staff surgeons completed >50% of the critical portions of the operation. We compared 30-day morbidity outcomes, overall survival (OS), and disease-free survival (DFS). Results: Three hundred thirteen patients met inclusion criteria. Demographic and clinical characteristics were similar between groups, as were types of surgical resection and median operative times. A statistical difference was found in the distribution of surgical approach. The odds of morbidity were 65% higher in the Staff group (OR=1.65; 95% CI, 1.007-2.71). Resident participation was not significantly associated with OS or DFS (P =.32 and P =.54, respectively). Discussion: General surgery resident involvement in lung cancer operations is not associated with longer operative times but is associated with a higher likelihood of a thoracotomy. General surgery resident involvement was associated with decreased postoperative morbidity and did not significantly affect OS or DFS.
In addition to the routine physical therapy program, Instrument-assisted soft tissue mobilization will be applied 3 days a week, for a total of 18 sessions. Each session will last 5 minutes.
In order to investigate the effects of RNAi-mediated survivin and hypoxia-inducible factor 1α (HIF-1α) gene silencing on the proliferation and apoptosis of gastric cancer BGC-823 cells, small interfering RNAs (siRNAs) targeting survivin and HIF-1α mRNAs, respectively, as well as scrambled siRNAs (SCRs) were designed and synthesized, namely siRNA-survivin group, siRNA-HIF-1α group, and SCR group. The hypoxia-sensitive gastric cancer BGC-823 cells were identified and transfected in vitro with Hifectin II under hypoxic conditions, and the expression of survivin and HIF-1α was assessed by RT-PCR and Western blotting assays, respectively. The ability of apoptosis, proliferation, invasion, and migration was measured, and the results showed that HIF-1α expression was significantly increased in BGC-823 cells under hypoxic conditions, and survival-targeted siRNA transfection decreased the expression of survivin under hypoxic conditions, while co-transfection of survivin-targeted siRNA and HIF-1α-targeted siRNA down-regulated both survivin and HIF-1α expression. Compared with the blank control group, the co-transfected siRNA group exhibited distinct characteristics, with decreased invasion and migration ability, increased apoptosis, and significantly decreased cell proliferation under hypoxic conditions. It was confirmed that the downregulation of survivin and HIF-1α in BGC-823 cells may induce anticancer effects by enhancing apoptosis and decreasing proliferation, migration, and invasion ability. The novelty lies in the application of RNAi technology to silence the expression of both survivin and HIF-1α genes in gastric cancer BGC-823 cells by single and combined interference in an established gastric cancer cell model and observed the mechanism of its effect on the proliferation and apoptosis of gastric cancer cells. Concerning the success of this highly active antiretroviral therapy of gene disruption therapies, which is the first of its kind in the world, we wonder whether we can find other better gene targets for more kinds of tumor therapy.
OBJECTIVE: Many studies have reported microbial signatures in thrombi at major vascular sites, such as the coronary artery and the middle cerebral artery, which are critical for maintaining proper blood flow and oxygenation. Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition involving non-resolving thrombosis that has not been fully studied. This study explored the microbial taxonomy and functional profiles of both fresh and organized thrombi associated with CTEPH to investigate the role of microbiota in thrombus non-resolving.
METHODS: In this study, 12 CTEPH fresh thrombi and 12 organized thrombi were collected from 14 patients with CTEPH. Metagenomic sequencing was employed to explore the genomic information of all microorganisms in the thrombus samples.
RESULTS: Our data demonstrated a diverse range of microorganisms in CTEPH thrombi, whether fresh or organized. Notably, a considerable proportion (54.7 %) of sequencing data could not be classified into the relative microbial taxa, highlighting the complexity and novelty of the thrombus ecosystem. Although there were no significant differences in microbial community structure between the two groups, the abundance of dominant microbial species varied. Leuconostoc sp. DORA 2, Staphylococcus aureus, and Aliidongia dinghuensis were common dominant species in CTEPH thrombus. Organized thrombus significantly increased the relative abundance of Staphylococcus aureus, which was confirmed to effectively distinguish between organized and fresh thrombi by LeFSe analysis and random forest analysis. Functional annotation using both the KEGG and eggNOG databases revealed that organized thrombi exhibit stronger metabolic functions, particularly in amino acid metabolism.
CONCLUSIONS: Our findings suggest that microbial composition and function may play an important role in thrombus organization. Targeting inflammation to prevent thrombosis presents promising opportunities for further research in this area.
OBJECTIVE: The objective of this study was to investigate whether an obesity-related inflammatory protein signature (OIPS) is associated with adverse cardiovascular events.
METHODS: The Olink Target 96 Inflammation panel was performed in 6662 participants from the population-based Gutenberg Health Study (GHS). The OIPS was selected by a logistic regression model, and its association with cardiovascular outcomes was evaluated by Cox regression analysis. The GHS-derived OIPS was externally validated in the MyoVasc study.
RESULTS: The identified OIPS entailed 21 proteins involved in chemokine activity, tumor necrosis factor (TNF) receptor binding, and growth factor receptor binding. The signature revealed a novel positive association of axis inhibition protein 1 with obesity. The OIPS was associated with increased risk of all-cause and cardiac deaths, major adverse cardiovascular events, and incident coronary artery disease, independent of clinical covariates and established risk instruments. A BMI-stratified analysis confirmed the association of OIPS with increased death in those with obesity and overweight and with increased risk for coronary artery disease in those with obesity. The association of OIPS with increased risk of all-cause and cardiac deaths was validated in the MyoVasc cohort.
CONCLUSIONS: The OIPS showed a significant association with adverse clinical outcomes, particularly in those with overweight and obesity, and represents a promising tool for identifying patients at higher risk for worse cardiovascular outcomes.
The intervention protocol will combine a home-based neck and shoulder exercise program and the use of deep dry needling in distant area from the location of active or latent myofascial trigger points of different neck-shoulder muscles. Therefore, dry needling will be applied in the same muscle but at a remote site from the locus of the myofascial trigger point, and, therefore, without evoking local twitch responses. Patients will receive 1 dry needling session a week during 3 weeks (3 sessions in total). They will also undergo the neck exercise program at home during these three weeks, and for the next three months.
BACKGROUND: Periprosthetic joint infection is a serious complication following joint replacement. The development of bacterial biofilms bestows antibiotic resistance and restricts treatment via implant retention surgery. Electromagnetic induction heating is a novel technique for antibacterial treatment of metallic surfaces that has demonstrated in-vitro efficacy. Previous studies have always employed stationary, non-portable devices. This study aims to assess the in-vitro efficacy of induction-heating disinfection of metallic surfaces using a new Portable Disinfection System based on Induction Heating.
METHODS: Mature biofilms of three bacterial species: S. epidermidis ATCC 35,984, S. aureus ATCC 25,923, E. coli ATCC 25,922, were grown on 18 × 2 mm cylindrical coupons of Titanium-Aluminium-Vanadium (Ti6Al4V) or Cobalt-chromium-molybdenum (CoCrMo) alloys. Study intervention was induction-heating of the coupon surface up to 70ºC for 210s, performed using the Portable Disinfection System (PDSIH). Temperature was monitored using thermographic imaging. For each bacterial strain and each metallic alloy, experiments and controls were conducted in triplicate. Bacterial load was quantified through scraping and drop plate techniques. Data were evaluated using non-parametric Mann-Whitney U test for 2 group comparison. Statistical significance was fixed at p ≤ 0.05.
RESULTS: All bacterial strains showed a statistically significant reduction of CFU per surface area in both materials. Bacterial load reduction amounted to 0.507 and 0.602 Log10 CFU/mL for S. aureus on Ti6Al4V and CoCrMo respectively, 5.937 and 3.500 Log10 CFU/mL for E. coli, and 1.222 and 0.372 Log10 CFU/mL for S. epidermidis.
CONCLUSIONS: Electromagnetic induction heating using PDSIH is efficacious to reduce mature biofilms of S aureus, E coli and S epidermidis growing on metallic surfaces of Ti6Al4V and CoCrMo alloys.
The invention provides a preparation method and a product of a multifunctional intestinal diagnosis and treatment preparation, wherein the multifunctional intestinal diagnosis and treatment preparation product simultaneously has a multifunctional probe for PET imaging, ultrasonic imaging and photothermal treatment, can simultaneously meet the requirements of accurate tumor positioning and high-sensitivity long-period imaging, and improves the targeting imaging efficiency of the probe on tumors. Macrophages are used as drug carriers "reservoirs". The carrier is enhanced to be enriched at the tumor part through the macrophage transportation function, and the chitosan can be effectively adsorbed on the surface of intestinal mucosa.  18  The F-type nuclide is used as an imaging agent of PET. The tumor position and the metastasis are determined through PET imaging, so that the accurate positioning of the whole body tumor is realized. Fluorocarbons are used as ultrasound contrast agents. By ultrasonic imaging, the diagnostic ability of local tumors is improved. The gold nanorods have a photo-thermal effect and have the effect of treating tumor parts.
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS) that preferentially affects young adults. While its etiology is unknown, current concepts assume that CD4+ helper T cells with specificity for components of the myelin sheath initiate the pathogenetic process. The activation and expansion of such autoreactive T cells involves the secretion of autocrine growth factors, particularly interleukin-2 (IL-2), and the concomitant expression of its receptor, IL-2R, on the surface of T cells. Since only activated T lymphocytes can migrate through the blood brain barrier into the CNS and induce the inflammatory process, blocking the IL-2R should have an impact on disease activity in MS.

In this trial , a humanized antibody against the IL-2Ra subunit (Zenapax(Registered Trademark)) will be used to inhibit T cell activation in MS patients who have failed conventional therapy by interferon-b. We will focus on the latter group of patients, since a substantial number of patients on conventional therapy respond only partially or completely fail treatment after longer periods of time. Up to 10 patients fulfilling these criteria will be enrolled in this baseline-to-treatment, cross-over, MRI-controlled single-center phase I/II trial to assess the safety of Zenapax(Registered Trademark) treatment and, at the same time, examine the clinical course and particularly the inflammatory activity in the CNS by monthly magnetic resonance imaging (MRI). Furthermore, immunological studies will be performed in parallel to the trial in order to a) identify the impact of Zenapax(Registered Trademark) treatment on immune parameters that should be affected by the blocking of the IL-2R, and b) to improve our understanding of the relevance of activated autoreactive T lymphocytes in MS.
An endogenous factor having an inhibitory activity on the growth of hair is identified. A substance having a similar activity of that of the endogenous factor or a substance capable of enhancing the activity or expression of the endogenous factor is screened. By utilizing the physiological activities of the substance, it is possible to provide a hair-removing agent or a hair growth-inhibiting agent. It is found that FGF18 can inhibit the growth of hair. Disclosed is a method for screening a substance having a FGF18-like activity, a substance capable of enhancing the FGF18 activity or a substance capable of enhancing the expression of FGF18 gene and employing the substance as a candidate for a hair growth-inhibiting agent or a hair-removing agent. Also disclosed is a hair growth-inhibiting agent or a hair-removing agent comprising, as an active ingredient, FGF18 and/or a substance having a FGF18-like activity (e.g., a partial peptide of FGF18, an extract from a seaweed Digenea simplex) and/or a substance capable of enhancing the activity or expression of FGF18.
Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
TMC435 is a protease inhibitor (PI) and is being investigated for treatment of chronic hepatitis C virus (HCV) infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin). The result of this study may provide dosing recommendations for TMC435 in patients with severe renal impairement. This is a Phase I, open-label (both participant and investigator know the name of the medication given at certain moment), to investigate the effect of severe renal impairment on the pharmacokinetics and safety of TMC435. Severe renal impairment will be defined by an estimated glomerular filtration rate (eGFR) = 29 mL/min/1.73m2. Participants with severe renal impairment are only allowed in this study if they are not on dialysis. Normal renal function will be considered as an eGFR = 80 mL/min/1.73m2. eGFR is a measured filtering capacity of the kidneys. The trial population will consist of a total of 16 male or female participants. Eight (8) healthy participants with a normal renal function and 8 participants with severe renal impairment will be included. A healthy participant will be matched to a participant with severe renal impairment with regards to sex, race, age (± 10 years), and body mass index (BMI) (± 20%). Dosing of the matched healthy participants can only start once the corresponding participants with severe renal impairment has completed Day 10 assessments (including physical examination). All participants will receive TMC435150 mg once a day (q.d.) for 7 days under fed conditions. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, on Day 1, Day 7, at the follow-up visit at 1 week after last dose of study medication and at the follow-up visit at 4-5 weeks after last dose of study medication. A physical examination will be performed at screening, on Day -1 (= day before first medication intake), on Day 10 and during the follow-up visits. A full pharmacokinetic profiles of bound TMC435 will be determined on Day 7 up to 72 hours postdose. In addition, unbound TMC435 plasma concentrations will be determined at specified timepoints. Safety and tolerability will be monitored throughout the trial. Participants will be admitted to the unit on Day-1 and discharged on Day10. Each participant will receive orally 150 mg TMC435, q.d. for 7 consecutive days.
Persisting ventilatory failure associated with chronic obstructive pulmonary disease (COPD), obesity-hypoventilation-syndrome, sleep apnoea or neuromuscular disease is increasingly managed with domiciliary non-invasive positive pressure ventilation (NIPPV).

Optimal settings of non-invasive ventilation are usually titrated manually and require time and expertise. The development of systems lead to automated analysis and development of algorithms to adjust ventilators. However, there is a paucity of optimal algorithms, particularly the problem of upper airway obstruction. Therefore, the central aim of this study is to develop the automated setting of an end-expiratory positive airway pressure (EPAP), because upper airway obstruction is relatively common in this group of patients. We hypothesise that an automated end-expiratory airway pressure (AutoEEP) adjusting algorithm could overcome these problems and further optimise and adjust ventilator settings. Using non-invasive ventilation in patients with hypercapnic ventilatory failure, awake and asleep, we will measure physiological outcome parameters and apply an AutoEEP algorithm, comparing it against usual care.
Active Treatment: Kron® (300ml) oral solution containing citicoline free acid 40 mg/ml; nicotinamide 15 mg/ml. In addition to the IOP-lowering medications, Kron will be administered at a dosage of 10 ml in the morning. To each patient will be given two bottles during the baseline visit and will be asked to return them at the end of the study (3 month) for the compliance assessment.
FIELD: medicinal microbiology, pharmaceutical industry. SUBSTANCE: preparation is used for immunotherapy of patients with staphylococcus infection and for treatment of patients nonsensitive to antibiotics or patients with staphylococcus infection if antibiotics cause allergic responses. Method involves conversion of toxin to anaform by treatment with formaldehyde. Anatoxin is purified by treatment with dry sodium chloride, precipitation with trichloroacetic acid, separation, precipitate dissolution in 0.9% sodium chloride solution and treatment with ethyl alcohol. Precipitate is separated by centrifugation and dissolved in 0.9% sodium chloride solution up to content 12 EC in 1 ml at residual formaldehyde content 0.003%, not above. Proposed method provides preparing nonreactive staphylococcus anatoxin purified from inert substances and without allergic responses. EFFECT: improved method of preparing, improved quality and properties of anatoxin. 1 cl, 1 tbl, 2 ex
Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
Pharmaceutical compsn. comprisess one or more anticancer drugs which are soluble in water but sparingly solbule in fats and/or oils, dispersed with an oil carrier in the presence of a solvent aid, e.g. a crown ether, lecithin, polyethylene glycol, propylene glycol, vitamin E, polyoxyethylene alkyl ether and sugar esters of fatty acids. Typical anticancer drugs are carmofur, 5fluorouracil, mitomycin-C, aclarubicin hydrochloride, ancitabin and doxorubicin hydrochloride, etc. The prods. are improved anticancer compsns.